Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Lung Cancer

  Free Subscription

Articles published in Cancer Lett

Retrieve available abstracts of 119 articles:
HTML format

Single Articles

    September 2022
  1. CHEN TW, Hung WZ, Chiang SF, Chen WT, et al
    Dual inhibition of TGFbeta signaling and CSF1/CSF1R reprograms tumor-infiltrating macrophages and improves response to chemotherapy via suppressing PD-L1.
    Cancer Lett. 2022;543:215795.
    PubMed     Abstract available

  2. ZHANG P, Li B, Chen Q, Wang H, et al
    Glucose restriction induces ROS-AMPK-mediated CTR1 expression and increases cisplatin efficiency in NSCLC.
    Cancer Lett. 2022;543:215793.
    PubMed     Abstract available

    August 2022
  3. ZHANG N, Gao Y, Huang Z, Dai P, et al
    PARP inhibitor plus radiotherapy reshapes an inflamed tumor microenvironment that sensitizes small cell lung cancer to the anti-PD-1 immunotherapy.
    Cancer Lett. 2022 Aug 1:215852. doi: 10.1016/j.canlet.2022.215852.
    PubMed     Abstract available

    July 2022
  4. SHANG C, Sun Y, Wang Y, Shi H, et al
    CXCL10 conditions alveolar macrophages within the premetastatic niche to promote metastasis.
    Cancer Lett. 2022;537:215667.
    PubMed     Abstract available

    June 2022
  5. LI J, Zhang Q, Jiang D, Shao J, et al
    CircRNAs in lung cancer- role and clinical application.
    Cancer Lett. 2022 Jun 30:215810. doi: 10.1016/j.canlet.2022.215810.
    PubMed     Abstract available

  6. YIN H, Wang X, Zhang X, Zeng Y, et al
    Corrigendum to "UBE2T promotes radiation resistance in non-small cell lung cancer via inducing epithelial-mesenchymal transition and the ubiquitination-mediated FOXO1 degradation" [Canc. Lett. 494 (2020) 121-131].
    Cancer Lett. 2022 Jun 16:215792. doi: 10.1016/j.canlet.2022.215792.

  7. CHEN B, Song Y, Zhan Y, Zhou S, et al
    Fangchinoline inhibits non-small cell lung cancer metastasis by reversing epithelial-mesenchymal transition and suppressing the cytosolic ROS-related Akt-mTOR signaling pathway.
    Cancer Lett. 2022 Jun 11:215783. doi: 10.1016/j.canlet.2022.215783.
    PubMed     Abstract available

  8. LI S, Qu Y, Liu L, Zhang X, et al
    Proteomic analysis of plasma-derived exosomes identifies biomarkers that distinguish brain and liver metastasis in lung cancer patients.
    Cancer Lett. 2022 Jun 9:215782. doi: 10.1016/j.canlet.2022.215782.
    PubMed     Abstract available

  9. GAO J, Zhang LX, Ao YQ, Jin C, et al
    Elevated circASCC3 limits antitumor immunity by sponging miR-432-5p to upregulate C5a in non-small cell lung cancer.
    Cancer Lett. 2022;543:215774.
    PubMed     Abstract available

    May 2022
  10. SUN Y, Sun H, Qi Y, Pan M, et al
    Ring finger protein 6 enhances chemo-resistance by transcriptionally activating proliferating cell nuclear antigen expression and attenuating DNA damage in lung adenocarcinoma.
    Cancer Lett. 2022;534:215609.
    PubMed     Abstract available

  11. TIAN Y, Ma J, Jing X, Zhai X, et al
    Radiation therapy for extensive-stage small-cell lung cancer in the era of immunotherapy.
    Cancer Lett. 2022;541:215719.
    PubMed     Abstract available

    April 2022
  12. LOU Y, Lu J, Zhang Y, Gu P, et al
    The centromere-associated protein CENPU promotes cell proliferation, migration, and invasiveness in lung adenocarcinoma.
    Cancer Lett. 2022;532:215599.
    PubMed     Abstract available

  13. SHI Y, Xu Y, Xu Z, Wang H, et al
    TKI resistant-based prognostic immune related gene signature in LUAD, in which FSCN1 contributes to tumor progression.
    Cancer Lett. 2022;532:215583.
    PubMed     Abstract available

  14. TSENG PC, Chen CL, Lee KY, Feng PH, et al
    Epithelial-to-mesenchymal transition hinders interferon-gamma-dependent immunosurveillance in lung cancer cells.
    Cancer Lett. 2022 Apr 28:215712. doi: 10.1016/j.canlet.2022.215712.
    PubMed     Abstract available

  15. TAROMI S, Firat E, Simonis A, Braun LM, et al
    Enhanced AC133-specific CAR T cell therapy induces durable remissions in mice with metastatic small cell lung cancer.
    Cancer Lett. 2022 Apr 26:215697. doi: 10.1016/j.canlet.2022.215697.
    PubMed     Abstract available

  16. FU L, Deng R, Huang Y, Yang X, et al
    Corrigendum to "DGKA interacts with SRC/FAK to promote the metastasis of non-small cell lung cancer" [Canc. Lett. (2022 Apr 28) 532 215585].
    Cancer Lett. 2022 Apr 24:215696. doi: 10.1016/j.canlet.2022.215696.

  17. TAROMI S, Firat E, Simonis A, Braun LM, et al
    Retraction notice to "Enhanced AC133-specific CAR T cell therapy induces durable remissions in mice with metastatic small cell lung cancer" [Canc. Lett. 520 (2021) 385-399].
    Cancer Lett. 2022 Apr 20:215680. doi: 10.1016/j.canlet.2022.215680.
    PubMed     Abstract available

  18. YAN R, Fan X, Xiao Z, Liu H, et al
    Inhibition of DCLK1 sensitizes resistant lung adenocarcinomas to EGFR-TKI through suppression of Wnt/beta-Catenin activity and cancer stemness.
    Cancer Lett. 2022;531:83-97.
    PubMed     Abstract available

    March 2022
  19. WANG J, Wren JD, Ding Y, Chen J, et al
    EWI2 promotes endolysosome-mediated turnover of growth factor receptors and integrins to suppress lung cancer.
    Cancer Lett. 2022 Mar 23:215641. doi: 10.1016/j.canlet.2022.215641.
    PubMed     Abstract available

    February 2022
  20. CHEN H, Zhao L, Meng Y, Qian X, et al
    Sulfonylurea receptor 1-expressing cancer cells induce cancer-associated fibroblasts to promote non-small cell lung cancer progression.
    Cancer Lett. 2022 Feb 28:215611. doi: 10.1016/j.canlet.2022.215611.
    PubMed     Abstract available

  21. SCHREIBER C, Gruber A, Rosswag S, Saraswati S, et al
    Loss of ASAP1 in the MMTV-PyMT model of luminal breast cancer activates AKT, accelerates tumorigenesis, and promotes metastasis.
    Cancer Lett. 2022 Feb 15:215600. doi: 10.1016/j.canlet.2022.215600.
    PubMed     Abstract available

  22. YANG X, Zeng Z, Jie X, Wang Y, et al
    Arginine methyltransferase PRMT5 methylates and destabilizes Mxi1 to confer radioresistance in non-small cell lung cancer.
    Cancer Lett. 2022;532:215594.
    PubMed     Abstract available

  23. FU L, Deng R, Huang Y, Yang X, et al
    DGKA interacts with SRC/FAK to promote the metastasis of non-small cell lung cancer.
    Cancer Lett. 2022 Feb 4:215585. doi: 10.1016/j.canlet.2022.215585.
    PubMed     Abstract available

  24. WEI K, Ma Z, Yang F, Zhao X, et al
    M2 macrophage-derived exosomes promote lung adenocarcinoma progression by delivering miR-942.
    Cancer Lett. 2022;526:205-216.
    PubMed     Abstract available

  25. FISK JN, Mahal AR, Dornburg A, Gaffney SG, et al
    Premetastatic shifts of endogenous and exogenous mutational processes support consolidative therapy in EGFR-driven lung adenocarcinoma.
    Cancer Lett. 2022;526:346-351.
    PubMed     Abstract available

  26. ZHANG K, Chen J, Li C, Yuan Y, et al
    Exosome-mediated transfer of SNHG7 enhances docetaxel resistance in lung adenocarcinoma.
    Cancer Lett. 2022;526:142-154.
    PubMed     Abstract available

    January 2022
  27. CHENG Z, Lu C, Wang H, Wang N, et al
    Long noncoding RNA LHFPL3-AS2 suppresses metastasis of non-small cell lung cancer by interacting with SFPQ to regulate TXNIP expression.
    Cancer Lett. 2022;531:1-13.
    PubMed     Abstract available

  28. LUO F, Lu FT, Cao JX, Ma WJ, et al
    HIF-1alpha inhibition promotes the efficacy of immune checkpoint blockade in the treatment of non-small cell lung cancer.
    Cancer Lett. 2022 Jan 25. pii: S0304-3835(22)00043.
    PubMed     Abstract available

  29. GOU W, Yu X, Wu S, Wu H, et al
    Targeted inhibition of acidic nucleoplasmic DNA-binding protein 1 enhances radiosensitivity of non-small cell lung cancer.
    Cancer Lett. 2022 Jan 19. pii: S0304-3835(22)00036.
    PubMed     Abstract available

  30. CHEN F, Liu J, Song X, DuCote TJ, et al
    EZH2 inhibition confers PIK3CA-driven lung tumors enhanced sensitivity to PI3K inhibition.
    Cancer Lett. 2022;524:151-160.
    PubMed     Abstract available

    December 2021
  31. CHAKRABORTY S, Utter MB, Frias MA, Foster DA, et al
    Cancer cells with defective RB and CDKN2A are resistant to the apoptotic effects of rapamycin.
    Cancer Lett. 2021;522:164-170.
    PubMed     Abstract available

    November 2021
  32. LIU S, Zhan N, Gao C, Xu P, et al
    Long noncoding RNA CBR3-AS1 mediates tumorigenesis and radiosensitivity of non-small cell lung cancer through redox and DNA repair by CBR3-AS1 /miR-409-3p/SOD1 axis.
    Cancer Lett. 2021;526:1-11.
    PubMed     Abstract available

  33. WANG T, Liu Z, She Y, Deng J, et al
    A novel protein encoded by circASK1 ameliorates gefitinib resistance in lung adenocarcinoma by competitively activating ASK1-dependent apoptosis.
    Cancer Lett. 2021;520:321-331.
    PubMed     Abstract available

  34. MEEUSEN B, Cortesi EE, Domenech Omella J, Sablina A, et al
    PPP2R4 dysfunction promotes KRAS-mutant lung adenocarcinoma development and mediates opposite responses to MEK and mTOR inhibition.
    Cancer Lett. 2021;520:57-67.
    PubMed     Abstract available

    October 2021
  35. GONG L, Shu J, Chen X, Pan H, et al
    DEPTOR inhibits lung tumorigenesis by inactivating the EGFR-mTOR signals.
    Cancer Lett. 2021;519:263-276.
    PubMed     Abstract available

  36. ZHAO W, Yu D, Chen Z, Yao W, et al
    Inhibition of MEK5/ERK5 signaling overcomes acquired resistance to the third generation EGFR inhibitor, osimertinib, via enhancing Bim-dependent apoptosis.
    Cancer Lett. 2021;519:141-149.
    PubMed     Abstract available

  37. LIANG R
    Letter to the editor regarding "XPO1 inhibition synergizes with PARP1 inhibition in small cell lung cancer by targeting nuclear transport of FOXO3a".
    Cancer Lett. 2021;524:193.

  38. LIU C, Xiang X, Han S, Lim HY, et al
    Blood-based liquid biopsy: Insights into early detection and clinical management of lung cancer.
    Cancer Lett. 2021;524:91-102.
    PubMed     Abstract available

  39. ZHANG J, Wu Q, Zhu L, Xie S, et al
    SERPINE2/PN-1 regulates the DNA damage response and radioresistance by activating ATM in lung cancer.
    Cancer Lett. 2021 Oct 11. pii: S0304-3835(21)00511.
    PubMed     Abstract available

  40. DA COSTA V, van Vliet SJ, Carasi P, Frigerio S, et al
    The Tn antigen promotes lung tumor growth by fostering immunosuppression and angiogenesis via interaction with Macrophage Galactose-type lectin 2 (MGL2).
    Cancer Lett. 2021;518:72-81.
    PubMed     Abstract available

  41. TINGLEI H, Biying C, Feng W, Weiyang C, et al
    Rab1A promotes IL-4R/JAK1/STAT6-dependent metastasis and determines JAK1 inhibitor sensitivity in non-small cell lung cancer.
    Cancer Lett. 2021 Oct 7. pii: S0304-3835(21)00518.
    PubMed     Abstract available

    September 2021
  42. YANG F, Duan M, Zheng F, Yu L, et al
    Fas signaling in adipocytes promotes low-grade inflammation and lung metastasis of colorectal cancer through interaction with Bmx.
    Cancer Lett. 2021;522:93-104.
    PubMed     Abstract available

  43. TANIMURA K, Yamada T, Horinaka M, Katayama Y, et al
    Inhibition of c-Jun N-terminal kinase signaling increased apoptosis and prevented the emergence of ALK-TKI-tolerant cells in ALK-rearranged non-small cell lung cancer.
    Cancer Lett. 2021;522:119-128.
    PubMed     Abstract available

  44. XU Y, Chen Y, Yao Y, Xie H, et al
    VIRMA contributes to non-small cell lung cancer progression via N(6)-methyladenosine-dependent DAPK3 post-transcriptional modification.
    Cancer Lett. 2021 Sep 11. pii: S0304-3835(21)00422.
    PubMed     Abstract available

  45. WANG J, Dai Z, Miao Y, Zhao T, et al
    Carbon ion ((12)C(6+)) irradiation induces the expression of Klrk1 in lung cancer and optimizes the tumor microenvironment based on the NKG2D/NKG2D-Ls pathway.
    Cancer Lett. 2021;521:178-195.
    PubMed     Abstract available

    August 2021
  46. JIANG Y, Zhan H, Zhang Y, Yang J, et al
    ZIP4 promotes non-small cell lung cancer metastasis by activating snail-N-cadherin signaling axis.
    Cancer Lett. 2021 Aug 24. pii: S0304-3835(21)00420.
    PubMed     Abstract available

  47. PARK MS, Yang AY, Lee JE, Kim SK, et al
    GALNT3 suppresses lung cancer by inhibiting myeloid-derived suppressor cell infiltration and angiogenesis in a TNFR and c-MET pathway-dependent manner.
    Cancer Lett. 2021 Aug 17. pii: S0304-3835(21)00404.
    PubMed     Abstract available

  48. TAROMI S, Firat E, Simonis A, Braun LM, et al
    Enhanced AC133-specific CAR T cell therapy induces durable remissions in mice with metastatic small cell lung cancer.
    Cancer Lett. 2021 Aug 15. pii: S0304-3835(21)00401.
    PubMed     Abstract available

    July 2021
  49. LIN S, Li Y, Wang D, Huang C, et al
    Fascin promotes lung cancer growth and metastasis by enhancing glycolysis and PFKFB3 expression.
    Cancer Lett. 2021;518:230-242.
    PubMed     Abstract available

  50. JIN M, Li G, Liu W, Wu X, et al
    Cigarette smoking induces aberrant N(6)-methyladenosine of DAPK2 to promote non-small cell lung cancer progression by activating NF-kappaB pathway.
    Cancer Lett. 2021;518:214-229.
    PubMed     Abstract available

  51. HUANG J, Tian F, Song Y, Cao M, et al
    A feedback circuit comprising EHD1 and 14-3-3zeta sustains beta-catenin/c-Myc-mediated aerobic glycolysis and proliferation in non-small cell lung cancer.
    Cancer Lett. 2021;520:12-25.
    PubMed     Abstract available

    June 2021
  52. HAN HJ, Sung JY, Kim SH, Yun UJ, et al
    Fibronectin regulates anoikis resistance via cell aggregate formation.
    Cancer Lett. 2021;508:59-72.
    PubMed     Abstract available

  53. ZHANG J, Zeng Y, Xing Y, Li X, et al
    Myristoylation-mediated phase separation of EZH2 compartmentalizes STAT3 to promote lung cancer growth.
    Cancer Lett. 2021 Jun 5. pii: S0304-3835(21)00266.
    PubMed     Abstract available

  54. GABASA M, Radisky ES, Ikemori R, Bertolini G, et al
    MMP1 drives tumor progression in large cell carcinoma of the lung through fibroblast senescence.
    Cancer Lett. 2021;507:1-12.
    PubMed     Abstract available

    May 2021
  55. JIANG ZB, Wang WJ, Xu C, Xie YJ, et al
    Luteolin and its derivative apigenin suppress the inducible PD-L1 expression to improve anti-tumor immunity in KRAS-mutant lung cancer.
    Cancer Lett. 2021;515:36-48.
    PubMed     Abstract available

  56. ZHANG H, Jiang H, Zhu L, Li J, et al
    Cancer-associated fibroblasts in non-small cell lung cancer: Recent advances and future perspectives.
    Cancer Lett. 2021 May 18. pii: S0304-3835(21)00224.
    PubMed     Abstract available

    April 2021
  57. WANG J, Hu T, Wang Q, Chen R, et al
    Repression of the AURKA-CXCL5 axis induces autophagic cell death and promotes radiosensitivity in non-small-cell lung cancer.
    Cancer Lett. 2021;509:89-104.
    PubMed     Abstract available

    March 2021
  58. LIN CY, Huang KY, Lin YC, Yang SC, et al
    Vorinostat combined with brigatinib overcomes acquired resistance in EGFR-C797S-mutated lung cancer.
    Cancer Lett. 2021;508:76-91.
    PubMed     Abstract available

  59. LEE S, Hong JH, Kim JS, Yoon JS, et al
    Cancer-associated fibroblasts activated by miR-196a promote the migration and invasion of lung cancer cells.
    Cancer Lett. 2021;508:92-103.
    PubMed     Abstract available

  60. MA Y, Wang L, He F, Yang J, et al
    LACTB suppresses melanoma progression by attenuating PP1A and YAP interaction.
    Cancer Lett. 2021 Mar 3. pii: S0304-3835(21)00101.
    PubMed     Abstract available

  61. TRAVER G, Sekhar KR, Crooks PA, Keeney DS, et al
    Targeting NPM1 in irradiated cells inhibits NPM1 binding to RAD51, RAD51 foci formation and radiosensitizes NSCLC.
    Cancer Lett. 2021;500:220-227.
    PubMed     Abstract available

    February 2021
  62. DANG N, Lin Y, Waer M, Sprangers B, et al
    Immunization with alloantibodies-covered melanoma cells induces regional antitumor effects that become systemic when combined with 5-FU treatment.
    Cancer Lett. 2021;503:151-162.
    PubMed     Abstract available

    January 2021
  63. LI Y, Chen Y, Miao L, Wang Y, et al
    Stress-induced upregulation of TNFSF4 in cancer-associated fibroblast facilitates chemoresistance of lung adenocarcinoma through inhibiting apoptosis of tumor cells.
    Cancer Lett. 2021;497:212-220.
    PubMed     Abstract available

  64. WANG J, Sun T, Meng Z, Wang L, et al
    XPO1 inhibition synergizes with PARP1 inhibition in small cell lung cancer by targeting nuclear transport of FOXO3a.
    Cancer Lett. 2021 Jan 22. pii: S0304-3835(21)00024.
    PubMed     Abstract available

  65. LI X, Chen M, Lu W, Tang J, et al
    Targeting FAPalpha-expressing tumor-associated mesenchymal stromal cells inhibits triple-negative breast cancer pulmonary metastasis.
    Cancer Lett. 2021 Jan 19. pii: S0304-3835(21)00029.
    PubMed     Abstract available

  66. TANG S, Li S, Liu T, He Y, et al
    MicroRNAs: Emerging oncogenic and tumor-suppressive regulators, biomarkers and therapeutic targets in lung cancer.
    Cancer Lett. 2021;502:71-83.
    PubMed     Abstract available

  67. ZHOU S, Xie J, Huang Z, Deng L, et al
    Anti-PD-(L)1 immunotherapy for brain metastases in non-small cell lung cancer: Mechanisms, advances, and challenges.
    Cancer Lett. 2021 Jan 12. pii: S0304-3835(21)00008.
    PubMed     Abstract available

  68. GRILLO E, Corsini M, Ravelli C, di Somma M, et al
    A novel variant of VEGFR2 identified by a pan-cancer screening of recurrent somatic mutations in the catalytic domain of tyrosine kinase receptors enhances tumor growth and metastasis.
    Cancer Lett. 2021;496:84-92.
    PubMed     Abstract available

    December 2020
  69. LO SARDO F, Pulito C, Sacconi A, Korita E, et al
    YAP/TAZ and EZH2 synergize to impair tumor suppressor activity of TGFBR2 in non-small cell lung cancer.
    Cancer Lett. 2020 Dec 6. pii: S0304-3835(20)30636.
    PubMed     Abstract available

  70. YAO S, Shi F, Mu N, Li X, et al
    Angio-associated migratory cell protein (AAMP) interacts with cell division cycle 42 (CDC42) and enhances migration and invasion in human non-small cell lung cancer cells.
    Cancer Lett. 2020 Dec 3. pii: S0304-3835(20)30648.
    PubMed     Abstract available

  71. ZHOU L, Xu Q, Huang L, Jin J, et al
    Low-dose carboplatin reprograms tumor immune microenvironment through STING signaling pathway and synergizes with PD-1 inhibitors in lung cancer.
    Cancer Lett. 2020 Dec 2. pii: S0304-3835(20)30647.
    PubMed     Abstract available

  72. CHEN D, Wu X, Chen Y, Chen C, et al
    Comment on 'Clinical significance and inflammatory landscapes of a novel recurrence associated immune signature in early-stage lung adenocarcinoma'.
    Cancer Lett. 2020;494:17.

  73. SUN N, Zhang C, He J
    Response to comment on 'Clinical significance and inflammatory landscapes of a novel recurrence-associated immune signature in early-stage lung adenocarcinoma'.
    Cancer Lett. 2020;494:5-6.

    November 2020
  74. ZHENG Y, Wang Z, Wei S, Liu Z, et al
    Epigenetic silencing of chemokine CCL2 represses macrophage infiltration to potentiate tumor development in small cell lung cancer.
    Cancer Lett. 2020 Nov 28. pii: S0304-3835(20)30632.
    PubMed     Abstract available

  75. XIE J, Yang P, Lin HP, Li Y, et al
    Integrin alpha4 up-regulation activates the hedgehog pathway to promote arsenic and benzo[alpha]pyrene co-exposure-induced cancer stem cell-like property and tumorigenesis.
    Cancer Lett. 2020;493:143-155.
    PubMed     Abstract available

  76. YAO C, Su L, Zhang F, Zhu X, et al
    Thevebioside, the active ingredient of traditional Chinese medicine, promotes ubiquitin-mediated SRC-3 degradation to induce NSCLC cells apoptosis.
    Cancer Lett. 2020;493:167-177.
    PubMed     Abstract available

  77. YUAN J, Xing H, Li Y, Song Y, et al
    EPB41 suppresses the Wnt/beta-catenin signaling in non-small cell lung cancer by sponging ALDOC.
    Cancer Lett. 2020 Nov 24. pii: S0304-3835(20)30622.
    PubMed     Abstract available

  78. SHIH CT, Shiau CW, Chen YL, Chen LJ, et al
    TD-92, a novel erlotinib derivative, depletes tumor-associated macrophages in non-small cell lung cancer via down-regulation of CSF-1R and enhances the anti-tumor effects of anti-PD-1.
    Cancer Lett. 2020 Nov 21. pii: S0304-3835(20)30577.
    PubMed     Abstract available

  79. LI J, Gao A, Zhang F, Wang S, et al
    ILT3 promotes tumor cell motility and angiogenesis in non-small cell lung cancer.
    Cancer Lett. 2020 Nov 2. pii: S0304-3835(20)30582.
    PubMed     Abstract available

    October 2020
  80. PHAM K, Huynh D, Le L, Delitto D, et al
    E-cigarette promotes breast carcinoma progression and lung metastasis: Macrophage-tumor cells crosstalk and the role of CCL5 and VCAM-1.
    Cancer Lett. 2020;491:132-145.
    PubMed     Abstract available

  81. MULET M, Zamora C, Porcel JM, Nieto JC, et al
    Platelet factor 4 regulates T cell effector functions in malignant pleural effusions.
    Cancer Lett. 2020;491:78-86.
    PubMed     Abstract available

  82. HAQUE A, Rahman MA, Fuchs JR, Chen Z, et al
    Corrigendum to "FLLL12 induces apoptosis in lung cancer cells through a p53/p73-independent but death receptor 5-dependent pathway" [Canc. Lett. 363 (2015) 166-175].
    Cancer Lett. 2020 Oct 20. pii: S0304-3835(20)30395.

  83. MIYASHITA N, Horie M, Mikami Y, Urushiyama H, et al
    ASCL1 promotes tumor progression through cell-autonomous signaling and immune modulation in a subset of lung adenocarcinoma.
    Cancer Lett. 2020;489:121-132.
    PubMed     Abstract available

    September 2020
  84. PARK S, Kim TM, Cho SY, Kim S, et al
    Combined blockade of polo-like kinase and pan-RAF is effective against NRAS-mutant non-small cell lung cancer cells.
    Cancer Lett. 2020;495:135-144.
    PubMed     Abstract available

  85. QUAN C, Chen Y, Wang X, Yang D, et al
    Loss of histone lysine methyltransferase EZH2 confers resistance to tyrosine kinase inhibitors in non-small cell lung cancer.
    Cancer Lett. 2020 Sep 10. pii: S0304-3835(20)30465.
    PubMed     Abstract available

  86. MAHMUD F, Deng S, Chen H, Miller DD, et al
    Orally available tubulin inhibitor VERU-111 enhances antitumor efficacy in paclitaxel-resistant lung cancer.
    Cancer Lett. 2020 Sep 10. pii: S0304-3835(20)30466.
    PubMed     Abstract available

  87. ZENG Y, Jie X, Wu B, Wu G, et al
    IQGAP3 interacts with Rad17 to recruit the Mre11-Rad50-Nbs1 complex and contributes to radioresistance in lung cancer.
    Cancer Lett. 2020 Sep 4. pii: S0304-3835(20)30456.
    PubMed     Abstract available

    August 2020
  88. CHEN C, Liu WR, Zhang B, Zhang LM, et al
    LncRNA H19 downregulation confers erlotinib resistance through upregulation of PKM2 and phosphorylation of AKT in EGFR-mutant lung cancers.
    Cancer Lett. 2020;486:58-70.
    PubMed     Abstract available

  89. WANG C, Tan S, Li J, Liu WR, et al
    CircRNAs in lung cancer - Biogenesis, function and clinical implication.
    Cancer Lett. 2020 Aug 26. pii: S0304-3835(20)30427.
    PubMed     Abstract available

  90. SHOU J, You L, Yao J, Xie J, et al
    Corrigendum to "Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3" [Canc Lett 379 (2016) 124-133].
    Cancer Lett. 2020;493:13-15.

  91. TIAN D, Tang J, Geng X, Li Q, et al
    Targeting UHRF1-dependent DNA repair selectively sensitizes KRAS mutant lung cancer to chemotherapy.
    Cancer Lett. 2020 Aug 16. pii: S0304-3835(20)30421.
    PubMed     Abstract available

  92. CASAL-MOURINO A, Ruano-Ravina A, Torres-Duran M, Parente-Lamelas I, et al
    Corrigendum to "Lung cancer survival in never-smokers and exposure to residential radon: Results of the LCRINS study" [Canc. Lett. 487 (2020) 21-26].
    Cancer Lett. 2020;493:10.

  93. TEOH ST, Ogrodzinski MP, Lunt SY
    UDP-glucose 6-dehydrogenase knockout impairs migration and decreases in vivo metastatic ability of breast cancer cells.
    Cancer Lett. 2020 Aug 5. pii: S0304-3835(20)30388.
    PubMed     Abstract available

  94. WANG D, Cong J, Fu B, Zheng X, et al
    Immunogenic chemotherapy effectively inhibits KRAS-Driven lung cancer.
    Cancer Lett. 2020 Aug 3. pii: S0304-3835(20)30399.
    PubMed     Abstract available

  95. GALLAND S, Martin P, Fregni G, Letovanec I, et al
    Attenuation of the pro-inflammatory signature of lung cancer-derived mesenchymal stromal cells by statins.
    Cancer Lett. 2020;484:50-64.
    PubMed     Abstract available

    July 2020
  96. ZHOU W, Liu Y, Gao Y, Cheng Y, et al
    MICAL2 is a novel nucleocytoplasmic shuttling protein promoting cancer invasion and growth of lung adenocarcinoma.
    Cancer Lett. 2020;483:75-86.
    PubMed     Abstract available

  97. JIN R, Wang X, Zang R, Liu C, et al
    Desmoglein-2 modulates tumor progression and osimertinib drug resistance through the EGFR/Src/PAK1 pathway in lung adenocarcinoma.
    Cancer Lett. 2020;483:46-58.
    PubMed     Abstract available

  98. XU L, Hu H, Zheng LS, Wang MY, et al
    ETV4 is a theranostic target in clear cell renal cell carcinoma that promotes metastasis by activating the pro-metastatic gene FOSL1 in a PI3K-AKT dependent manner.
    Cancer Lett. 2020;482:74-89.
    PubMed     Abstract available

  99. OGAWA K, Lin Q, Li L, Bai X, et al
    Prometastatic secretome trafficking via exosomes initiates pancreatic cancer pulmonary metastasis.
    Cancer Lett. 2020;481:63-75.
    PubMed     Abstract available

    June 2020
  100. YIN H, Wang X, Zhang X, Zeng Y, et al
    UBE2T promotes radiation resistance in non-small cell lung cancer via inducing epithelial-mesenchymal transition and the ubiquitination-mediated FOXO1 degradation.
    Cancer Lett. 2020 Jun 23. pii: S0304-3835(20)30331.
    PubMed     Abstract available

  101. HUANG XH, Yan X, Zhang QH, Hong P, et al
    Direct targeting of HSP90 with daurisoline destabilizes beta-catenin to suppress lung cancer tumorigenesis.
    Cancer Lett. 2020 Jun 13. pii: S0304-3835(20)30286.
    PubMed     Abstract available

  102. ZHANG C, Zhang Z, Zhang G, Zhang Z, et al
    Clinical significance and inflammatory landscapes of a novel recurrence-associated immune signature in early-stage lung adenocarcinoma.
    Cancer Lett. 2020;479:31-41.
    PubMed     Abstract available

  103. HUANG F, Ma G, Zhou X, Zhu X, et al
    Depletion of LAMP3 enhances PKA-mediated VASP phosphorylation to suppress invasion and metastasis in esophageal squamous cell carcinoma.
    Cancer Lett. 2020;479:100-111.
    PubMed     Abstract available

    May 2020
  104. MOURINO AC, Ruano-Ravina A, Torres-Duran M, Parente-Lamelas I, et al
    Lung cancer survival in never-smokers and exposure to residential radon: Results of the LCRINS study.
    Cancer Lett. 2020 May 23. pii: S0304-3835(20)30284.
    PubMed     Abstract available

  105. ZHAO Z, Zhang N, Li A, Zhou B, et al
    Insulin-like growth factor-1 receptor induces immunosuppression in lung cancer by upregulating B7-H4 expression through the MEK/ERK signaling pathway.
    Cancer Lett. 2020 May 14. pii: S0304-3835(20)30199.
    PubMed     Abstract available

  106. YANG YF, Wang YY, Hsiao M, Lo S, et al
    IMPAD1 functions as mitochondrial electron transport inhibitor that prevents ROS production and promotes lung cancer metastasis through the AMPK-Notch1-HEY1 pathway.
    Cancer Lett. 2020 May 14. pii: S0304-3835(20)30227.
    PubMed     Abstract available

    April 2020
  107. ACHYUT BR, Zhang H, Angara K, Mivechi NF, et al
    Oncoprotein GT198 vaccination delays tumor growth in MMTV-PyMT mice.
    Cancer Lett. 2020;476:57-66.
    PubMed     Abstract available

  108. CHEN J, Liu A, Lin Z, Wang B, et al
    Downregulation of the Circadian Rhythm Regulator HLF Promotes Multiple-Organ Distant Metastases in Non-Small Cell Lung Cancer through PPAR/NF-kappaB Signaling.
    Cancer Lett. 2020 Apr 11. pii: S0304-3835(20)30184.
    PubMed     Abstract available

  109. WANG J, Li X, Chen H
    Organoid models in lung regeneration and cancer.
    Cancer Lett. 2020;475:129-135.
    PubMed     Abstract available

  110. KIM DH, Park S, Kim H, Choi YJ, et al
    Tumor-derived exosomal miR-619-5p promotes tumor angiogenesis and metastasis through the inhibition of RCAN1.4.
    Cancer Lett. 2020;475:2-13.
    PubMed     Abstract available

  111. WANG J, Wu X, Dai W, Li J, et al
    The CCDC43-ADRM1 axis regulated by YY1, promotes proliferation and metastasis of gastric cancer.
    Cancer Lett. 2020 Apr 8. pii: S0304-3835(20)30159.
    PubMed     Abstract available

  112. KUO CL, Chou HY, Chiu YC, Cheng AN, et al
    Mitochondrial oxidative stress by Lon-PYCR1 maintains an immunosuppressive tumor microenvironment that promotes cancer progression and metastasis.
    Cancer Lett. 2020;474:138-150.
    PubMed     Abstract available

  113. ALMACELLAS-RABAIGET O, Monaco P, Huertas-Martinez J, Garcia-Monclus S, et al
    LOXL2 promotes oncogenic progression in alveolar rhabdomyosarcoma independently of its catalytic activity.
    Cancer Lett. 2020;474:1-14.
    PubMed     Abstract available

    March 2020
  114. VANBERVLIET-DEFRANCE B, Delaunay T, Daunizeau T, Kepenekian V, et al
    Cisplatin unleashes Toll-like receptor 3-mediated apoptosis through the downregulation of c-FLIP in malignant mesothelioma.
    Cancer Lett. 2020;472:29-39.
    PubMed     Abstract available

    January 2020
  115. SEIDL C, Panzitt K, Bertsch A, Brcic L, et al
    MicroRNA-182-5p regulates hedgehog signaling pathway and chemosensitivity of cisplatin-resistant lung adenocarcinoma cells via targeting GLI2.
    Cancer Lett. 2020;469:266-276.
    PubMed     Abstract available

  116. ZHANG L, Zhang X, Liu Y, Zhang T, et al
    PD-L1(+) aneuploid circulating tumor endothelial cells (CTECs) exhibit resistance to the checkpoint blockade immunotherapy in advanced NSCLC patients.
    Cancer Lett. 2020;469:355-366.
    PubMed     Abstract available

    September 2019
  117. ZOU H, Chen H, Zhou Z, Wan Y, et al
    ATXN3 promotes breast cancer metastasis by deubiquitinating KLF4.
    Cancer Lett. 2019 Sep 26. pii: S0304-3835(19)30484.
    PubMed     Abstract available

    May 2019
  118. FLAHERTY RL, Intabli H, Falcinelli M, Bucca G, et al
    Stress hormone-mediated acceleration of breast cancer metastasis is halted by inhibition of nitric oxide synthase.
    Cancer Lett. 2019 May 24. pii: S0304-3835(19)30322.
    PubMed     Abstract available

  119. LI Y, Acharya G, Elahy M, Xin H, et al
    The Anthelmintic Flubendazole Blocks Human Melanoma Growth and Metastasis and Suppresses Programmed Cell Death Protein-1 and Myeloid-Derived Suppressor Cell Accumulation.
    Cancer Lett. 2019 May 22. pii: S0304-3835(19)30321.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.